

Special Issue

Biomarkers in the Management of Lung Cancer

Message from the Guest Editor

Lung cancer remains a formidable challenge in oncology, characterized by its diverse subtypes and often aggressive nature. The intricate landscape of lung malignancies, encompassing non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and various histological subtypes, underscores the need for precise diagnostic and therapeutic strategies. Despite advancements in treatment modalities, the prognosis for many lung cancer patients remains poor, necessitating innovative approaches to early detection and tailored interventions. In this collection of articles, we present an overview of the current state of biomarker research in lung cancer, exploring the significance of emerging markers such as tumor mutational burden, PD-L1 expression, and liquid-biopsy-based approaches. As we navigate the complex terrain of lung cancer biomarkers, the articles within this Special Issue will provide valuable insights into the ongoing efforts to unravel the intricacies of this challenging disease. From predictive markers guiding targeted therapies to the dynamic landscape of immunotherapy, we invite readers to explore the forefront of biomarker-driven precision medicine in lung cancer.

Guest Editor

Prof. Dr. Ole Hilberg
Sygehus Lillebælt, Vejle Sygehus Beriderbakken 4, 7100 Vejle, Denmark

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/275698

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)